Tandospirone in the Treatment of Generalised Anxiety Disorder and Mixed Anxiety-Depression

@article{Nishitsuji2004TandospironeIT,
  title={Tandospirone in the Treatment of Generalised Anxiety Disorder and Mixed Anxiety-Depression},
  author={Kyoko Nishitsuji and Hsiao-Lun To and Yuko Murakami and Kenji Kodama and D Kobayashi and Tetsuya Yamada and C Kubo and Kazunori Mine},
  journal={Clinical Drug Investigation},
  year={2004},
  volume={24},
  pages={121-126}
}

Tandospirone prevents stress-induced anxiety-like behavior and visceral hypersensitivity by suppressing theta oscillation enhancement via 5-HT1A receptors in the anterior cingulate cortex in rats

A novel mechanism by which tandospirone activates 5-HT1A receptors to relieve stress-induced anxiety and visceral hypersensitivity by suppressing theta oscillation enhancement in ACC is suggested.

NDT_A_366048 1653..1664

  • 2022

Relative Safety and Efficacy of Two Doses of Tandospirone Citrate for Generalized Anxiety Disorder: A Multicenter Randomized Controlled Trial

High doses of tandospirone may have advantages in relieving the somatic symptoms but also present disadvantages due to their high level, and both 60 mg/ day and 30 mg/day tandosphereirone show good efficacy in treating patients with GAD.

Safety and E cacy of Two Doses of Tandospirone Citrate for Generalized Anxiety Disorder: A Multicenter Randomized Controlled Trial

This dissertation aims to provide a history of psychiatry in China over a 50-year period from 1950 to 2000, and aims to establish a chronology of key events leading up to and including the Yangtze River floods.

Influence of 5-HT2A receptor function on anxiety-like behavior induced by a combination treatment with doxorubicin and cyclophosphamide in rats

The present results suggest that anxiety-like behavior induced by the combination of doxorubicin and cyclophosphamide is mediated by 5-HT2A receptors hyperactivity without an increase in 5- HT2A receptor levels in rats.

Tranquilizer/Anxiolytics: Tandospirone

  • Jie Li
  • NeuroPsychopharmacotherapy
  • 2021

5-HT1A Partial Agonist Tandospirone for Behavioral and Psychological Symptoms in Oldest-old Patients with Dementia at a Special Elderly Nursing Home

Tandospirone treatment showed few or no obvious adverse effects and significantly improved CGI-S scores, as well as total scores and many subscale scores on the NPI-12, in both the sample at large and the oldest-old participants.

Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes

Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options

A lack of randomized double-blind placebo- controlled trials for anxiety disorders and few studies comparing novel treatments to existing anxiolytic agents suggests that there needs to be further expansion in research of these novel pathways and larger-scale studies of promising agents with positive results from smaller trials.

References

SHOWING 1-10 OF 20 REFERENCES

The side effect profile of buspirone in comparison to active controls and placebo.

Trimipramine patients were more seriously ill on initial diagnosis and showed significantly more improvement at week 2 than amitriptyline patients and a trend toward fewer side effects, Thus, trimipramsine may be useful for patients particularly sensitive to side effects in whom evidence of early response is important.

An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression.

Clinical evidence is provided suggesting that buspirone augmentation may be a useful clinical alternative in depressed patients who fail to respond to a serotonin reuptake inhibitor.

Effects of tandospirone, a 5-HT1A receptor-related anxiolytic, on daytime sleepiness and psychomotor functions: a comparative double-blind study with diazepam.

The findings suggested the superiority of tandospirone to the benzodiazepine in terms of behavioral side effects, and the differential effects of the two anxiolytics on daytime sleepiness and psychomotor functions could be ascribable to the differences in their pharmacological mechanisms of actions.

Buspirone augmentation of antidepressant therapy.

Thirty outpatients meeting DSM-III-R or DSM-IV criteria for major depression, single or recurrent episode, and failing to respond to an adequate trial of an antidepressant received buspirone for 4 or 5 weeks in addition to their existing antidepressant.

The DSM-IV field trial for mixed anxiety-depression.

A mixed anxiety-depression category be included in the DSM-IV appendix for proposed diagnostic categories that need further study and a criteria set is proposed.

A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder.

The safety and antianxiety and antidepressive effects of buspirone were compared in a double-blind trial with those of diazepam and were nearly equivalent in relieving symptoms of both anxiety and depression in 100 patients.

The Anxiolytic Effects of the 5-Hydroxytryptamine-1A Agonist Tandospirone Before Otolaryngologic Surgery

Tandospirone, 10 and 30 mg, safely reduced preoperative anxiety to a similar extent as oral diazepam 10 mg in patients undergoing elective otolaryngologic surgery.

The assessment of anxiety states by rating.

  • M. Hamilton
  • Psychology
    The British journal of medical psychology
  • 1959